Nwam LLC Purchases New Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Nwam LLC purchased a new stake in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 910,476 shares of the biotechnology company's stock, valued at approximately $5,172,000. Nwam LLC owned approximately 1.07% of Anavex Life Sciences as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of AVXL. Renaissance Technologies LLC boosted its holdings in shares of Anavex Life Sciences by 483.8% in the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company's stock worth $1,968,000 after buying an additional 386,537 shares during the period. Virtu Financial LLC boosted its stake in Anavex Life Sciences by 87.5% in the 1st quarter. Virtu Financial LLC now owns 40,612 shares of the biotechnology company's stock worth $207,000 after purchasing an additional 18,954 shares during the period. Deerfield Management Company L.P. Series C acquired a new position in Anavex Life Sciences in the 2nd quarter worth approximately $346,000. Vanguard Group Inc. grew its position in Anavex Life Sciences by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 4,414,682 shares of the biotechnology company's stock worth $22,471,000 after purchasing an additional 54,034 shares in the last quarter. Finally, Private Advisor Group LLC raised its stake in Anavex Life Sciences by 10.3% during the 3rd quarter. Private Advisor Group LLC now owns 47,413 shares of the biotechnology company's stock valued at $269,000 after purchasing an additional 4,442 shares during the period. Institutional investors and hedge funds own 31.55% of the company's stock.

Anavex Life Sciences Price Performance

Shares of AVXL traded up $0.09 during trading hours on Friday, reaching $9.11. The company's stock had a trading volume of 1,975,533 shares, compared to its average volume of 1,707,761. The company has a 50 day moving average of $6.40 and a two-hundred day moving average of $5.52. Anavex Life Sciences Corp. has a 1-year low of $3.25 and a 1-year high of $10.45.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Anavex Life Sciences in a research report on Monday, November 4th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.